Alzheimer's Blood Test Predicts Future Symptoms

Scientists have developed a blood test, p-tau217, that may predict the likelihood of apparently healthy older adults developing Alzheimer's disease symptoms within the next five to 10 years. This development could significantly aid in identifying individuals for clinical trials aimed at testing potential Alzheimer's treatments or preventive strategies.

The research, published in JAMA, indicated that symptom-free older adults with very high p-tau217 levels faced a 38% risk of cognitive impairment over five years, escalating to 78% over a decade. While this test is presently utilized to diagnose Alzheimer's in individuals experiencing cognitive difficulties, its predictive capability is a key focus for future applications.

Experts emphasize that it is premature for healthy individuals to seek this test. Dr. Reisa Sperling advised waiting until effective interventions are available, recommending lifestyle choices like healthy eating, ample sleep, exercise, and social engagement for now. The test measures a form of tau protein, which correlates with the buildup of amyloid plaques and tau tangles, hallmark markers of Alzheimer's disease.

While scientists not involved in the study praised its findings, they also cautioned that the 10-year risk estimate has less certainty due to shorter follow-up periods for some participants. Other health factors, such as the risk of death from other causes or vascular dementia, could also influence predictions. Nevertheless, the p-tau217 test is considered a crucial piece of the puzzle in understanding Alzheimer's progression.